NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $0.98 +0.04 (+4.42%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.00 (+0.20%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Akebia Therapeutics Stock (NASDAQ:AKBA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$0.94▼$1.0050-Day Range$0.84▼$1.4052-Week Range$0.81▼$3.20Volume5.09 million shsAverage Volume8.67 million shsMarket Capitalization$271.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.90Consensus RatingHold Company Overview Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients with kidney disease and related conditions. The company’s research and commercial activities center on therapies intended to address anemia associated with chronic kidney disease, iron deficiency, and other complications affecting people with impaired kidney function. Akebia’s lead product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in the United States for the treatment of anemia due to chronic kidney disease in adults on dialysis. The company also markets Auryxia (ferric citrate), which is approved in the United States to control serum phosphorus levels in adults with chronic kidney disease on dialysis and to treat iron-deficiency anemia in adults with non-dialysis-dependent chronic kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. The company expanded its commercial operations through the acquisition of Keryx Biopharmaceuticals in 2018, which added Auryxia to its portfolio. Akebia serves the U.S. market and has pursued international development and commercialization activities for its kidney-disease therapies through regional partnerships and regulatory approvals.AI Generated. May Contain Errors. Read More Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 470th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAkebia Therapeutics has a consensus price target of $3.90, representing about 298.0% upside from its current price of $0.98.Amount of Analyst CoverageAkebia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 8.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Akebia Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.67% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 2.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 7.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.08 News SentimentAkebia Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,181.00 in company stock.Percentage Held by Insiders4.30% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKBA Stock News HeadlinesXTL Biopharmaceuticals (NASDAQ:XTLB) vs. Akebia Therapeutics (NASDAQ:AKBA) Critical ContrastSeptember 22 at 4:45 AM | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by BrokeragesSeptember 17, 2026 | americanbankingnews.comPass by August 7… or wait until 2027?History shows what happens when Washington clears a path for capital. Bitcoin runs. And altcoins detonate. One coin sits at the center of this shift. It plays the same infrastructure role Uniswap and PancakeSwap played in their earliest days… except this one has an administration actively building the runway. Smart money is already accumulating. Volume is hitting record highs. And the market cap is still under $2 billion.September 22 at 1:00 AM | Crypto 101 Media (Ad)Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from BTIG ResearchSeptember 17, 2026 | americanbankingnews.comAkebia Doses First Patient In Phase 2 Trial Of Ebribafusp For Rare Kidney DiseasesSeptember 14, 2026 | rttnews.comAkebia Therapeutics Doses First Patient in Phase 2 Ebribafusp TrialSeptember 14, 2026 | finance.yahoo.comAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesSeptember 14, 2026 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) Raised to Hold at Wall Street ZenSeptember 12, 2026 | americanbankingnews.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.61 at the beginning of 2026. Since then, AKBA stock has decreased by 39.1% and is now trading at $0.98. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The biopharmaceutical company earned $49.13 million during the quarter, compared to the consensus estimate of $48.85 million. Akebia Therapeutics had a negative net margin of 13.54% and a negative trailing twelve-month return on equity of 88.88%. Read the conference call transcript. When did Akebia Therapeutics IPO? Akebia Therapeutics (AKBA) raised $91 million in an initial public offering (IPO) on Thursday, March 20th 2014. The company issued 5,882,353 shares at a price of $14.00-$17.00 per share. Who are Akebia Therapeutics' major shareholders? Top institutional shareholders of Akebia Therapeutics include BlackRock Inc. (7.45%), State Street Corp (1.95%), Nantahala Capital Management LLC (0.72%) and Hennion & Walsh Asset Management Inc. (0.31%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, Erik Ostrowski, Nicholas Grund and Richard C Malabre. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and ExxonMobil (XOM). Company Calendar Last Earnings8/05/2026Today9/22/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 7 days, AKBA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees194Year Founded2007Price Target and Rating Average Price Target for Akebia Therapeutics$3.90 High Price Target$6.00 Low Price Target$1.00 Potential Upside/Downside+298.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net Margins-13.54% Pretax Margin-12.71% Return on Equity-88.88% Return on Assets-7.74% Debt Debt-to-Equity Ratio0.99 Current Ratio1.43 Quick Ratio1.35 Sales & Book Value Annual Sales$236.20 million Price / Sales1.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book8.17Miscellaneous Outstanding Shares277,110,000Free Float265,190,000Market Cap$271.57 million OptionableOptionable Beta0.19 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AKBA) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredWhy Did Trump's Sons Put Money Into THIS Drone Company?Eric Trump and Donald Trump Jr. are reportedly backing an American drone manufacturer competing for a share of...Tim Sykes | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts